MDRR vs PSTV

For growth investors, Medalist Diversified REIT, Inc.

(MDRR) is the stronger pick with 6. 8% revenue growth year-over-year, versus -10. 5% for Plus Therapeutics, Inc. (PSTV). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Medalist Diversified REIT, Inc.

(MDRR) delivered a total return of -33. 4%, compared to -99. 3% for Plus Therapeutics, Inc. (PSTV). Over 10 years, the gap is even starker: MDRR returned -80. 2% versus PSTV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medalist Diversified REIT, Inc.

(MDRR) is the lower-risk stock at -0. 35β versus Plus Therapeutics, Inc. 's 1. 82β — meaning PSTV is approximately -624% more volatile than MDRR relative to the S&P 500. On balance sheet safety, Medalist Diversified REIT, Inc. (MDRR) carries a lower debt/equity ratio of 3% versus 21% for Plus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medalist Diversified REIT, Inc.

(MDRR) is pulling ahead at 6. 8% versus -10. 5% for Plus Therapeutics, Inc. (PSTV). On earnings-per-share growth, the picture is similar: Plus Therapeutics, Inc. grew EPS 100. 0% year-over-year, compared to -79. 2% for Medalist Diversified REIT, Inc.. Over a 3-year CAGR, PSTV leads at 185. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medalist Diversified REIT, Inc.

(MDRR) is the more profitable company, earning -23. 0% net margin versus -429. 4% for Plus Therapeutics, Inc. — meaning it keeps -23. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDRR leads at 5. 3% versus -293. 5% for PSTV. At the gross margin level — before operating expenses — PSTV leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MDRR (4.

3% yield) pays a dividend. PSTV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medalist Diversified REIT, Inc.

(MDRR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 35), 4. 3% yield). Plus Therapeutics, Inc. (PSTV) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDRR: -80. 2%, PSTV: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MDRR (Real Estate) and PSTV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MDRR is a small-cap income-oriented stock; PSTV is a small-cap quality compounder stock. MDRR pays a dividend while PSTV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.